fbpx Skip to main content

Arbaclofen: New Clinical Trial

By September 11, 2013May 25th, 2021eMS News

Participants with multiple sclerosis
are needed for a research study on:


Arbaclofen

(an extended release anti-spasticity investigational medication)

Purpose of the study –

Researchers from the University of Colorado Anschutz Medical Campus are conducting a clinical trial to compare the effectiveness and safety of arbaclofen extended release tablets to baclofen in MS patients with muscle spasticity.  

You may be eligible to participate if you –

  • Are between 18 and 65 years old
  • Have clinically confirmed diagnosis of multiple sclerosis (MS)
  • Are suffering from muscle spasticity for at least 6 months as a result of MS 

Study participation involves –

  • Approximately 10 visits over 5-6 months on the University of Colorado Anschutz Medical Campus
  • Questionnaires, physical exams, and blood work
  • Compensation for time and travel

If you are interested, please contact Bhavini Patel by calling 303-724-6351 or by email at bhavini.patel@ucdenver.edu to learn more about the study.

University of Colorado Denver-Principal Investigator: Augusto Miravalle, MD

Western Institutional Review Board (WIRB) approved Protocol # OS440-3002.
            Version Date: 05/02/13 

Close Menu
Translate Site »
Skip to content